The leader of the U.S. Food & Drug Administration’s CBD Working Group is leaving the agency, FDA Acting Director Janet Woodcock announced this week. Amy Abernethy, FDA’s Principal Deputy Commissioner and Acting Chief Information Officer, joined the agency in 2019, and was named to head the CBD initiative that same year.
FDA CBD group leader departs
Support HempToday with a donation
We appreciate our paying subscribers and strive to deliver the most complete, well-researched and comprehensive news, analysis and commentary about the hemp industries. If you’d like to further support us, click below to make a donation.